UBS upgraded Option Care Health (OPCH) to Buy from Neutral with a price target of $40, up from $38. The company’s Q1 results evidenced strong earnings momentum, despite a $5M impact from Stelara, which was more muted than anticipated given inventory management actions taken by Option, the analyst tells investors in a research note. The firm sees an attractive entry point at current share levels and continues to believe the company will see benefits from a secular shift in site of care from institutional to the home.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Option Care Health: Strong Growth Prospects and Strategic Market Position Justify Buy Rating
- Option Care Health Reports Strong Q1 2025 Results
- Option Care Health’s Earnings Call Highlights Strong Growth
- Option Care Health: Strong Financial Performance and Raised Guidance Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue